https://charts.traderzeitung.de/phases/US5288723027
string(1418) "{"isin":"US5288723027","name":"Lexicon Pharmaceuticals Inc","stock_id_xnas":7874280,"stock_id_xnys":null,"generated_at":"2026-08-21 08:15:00","days":[{"date":"2026-08-18","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":2.415,"close_at":"2026-08-18 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-19","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":2.415,"close_at":"2026-08-19 21:59:00","complete":true,"perf_pct":0},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":2.175,"close_at":"2026-08-20 21:59:00","complete":true,"perf_pct":-9.9379},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":2.19,"close_at":"2026-08-20 22:56:00","complete":true,"perf_pct":0.6897}]}]}"
Lexicon Pharmaceuticals Aktie News & Nachrichten

Lexicon Pharmaceuticals Aktie News & Nachrichten

[WKN: A14SSK | Symbol: LXRX]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Lexicon Pharmaceuticals: Exklusive Partnerschaft mit Viatris bietet gemäß der Experten gigantisches Potenzial!

Lexicon Pharmaceuticals Inc. (LXRX) ist ein Biotech mit Fokus auf Behandlungsmethoden von schwerwiegenden...

  • 1
MT Newswires 06.08.2026 14:12 Uhr

--Earnings Flash (LXRX) Lexicon Pharmaceuticals verzeichnet Q2 Verlust von 0,07 USD je Aktie, verglichen mit FactSet-Schätzung von 0,05 USD Verlust

07:56 AM EDT, 08/06/2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 06.08.2026 13:59 Uhr

Earnings Flash (LXRX) Lexicon Pharmaceuticals, Inc. meldet Q2-Umsatz von 692.000 USD gegenüber FactSet-Schätzung von 4,0 Mio. USD

07:37 AM EDT, 06.08.2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 27.07.2026 15:01 Uhr

Lexicon Pharmaceuticals schließt Rekrutierung für Studie zu potenzieller Behandlung der hypertrophen Kardiomyopathie ab

09:00 AM EDT, 27.07.2026 (MT Newswires) -- Lexicon Pharmaceuticals (LXRX) hat nach eigenen Angaben die Patientenaufnahme und -randomisierung in einer